Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma.

[1]  D. Longo,et al.  Mantle-Cell Lymphoma. , 2022, The New England journal of medicine.

[2]  Michael L. Wang,et al.  Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. , 2021, Blood advances.

[3]  Michael L. Wang,et al.  KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. , 2020, The New England journal of medicine.

[4]  C. Visco,et al.  Efficacy of R‐BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy , 2020, British journal of haematology.

[5]  Michael L. Wang,et al.  Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma , 2019, Leukemia.

[6]  E. Kimby,et al.  15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau , 2016, British journal of haematology.

[7]  R. Advani,et al.  Postibrutinib outcomes in patients with mantle cell lymphoma. , 2016, Blood.

[8]  F. Cavalli,et al.  Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. , 2015, The New England journal of medicine.

[9]  Michael L. Wang,et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.

[10]  G. Pizzolo,et al.  Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Salles,et al.  CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. , 2013, Blood.

[12]  W. Hiddemann,et al.  A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study , 2009, Leukemia & lymphoma.

[13]  W. Hiddemann,et al.  Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma , 2007, Leukemia.

[14]  J. Leonard,et al.  Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.